Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine

Liver Transplantation

Volumn 11, Issue 7, 2005, Pages 807-813

  Lo, Chung Mau ^a   Liu, Chi Leung ^a   Lau, George K ^a   Chan, See Ching ^a   Ng, Irene O ^a   Fan, Sheung Tat ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; BAYHEP; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INTERLEUKIN 2 RECEPTOR ANTIBODY; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; VIRUS DNA;

ADD ON THERAPY; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DNA DETERMINATION; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HEPATITIS B; HUMAN; IMMUNOPROPHYLAXIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; NEPHROTOXICITY; POLYMERASE CHAIN REACTION; PREOPERATIVE CARE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECURRENT INFECTION; SURVIVAL RATE; THROMBOCYTOPENIC PURPURA; VIRUS REPLICATION;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; LAMIVUDINE; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MUTATION; PHOSPHONIC ACIDS; PROTEIN STRUCTURE, TERTIARY; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 22144463843     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20416     Document Type: Article

References (23)

1. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. N Eng J Med 1998;339:61-68.
2. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-210.
3. Jury of the International Consensus Conference on Indications of Liver Transplantation. Consensus statement on indications for liver transplantation: Paris, June 22-23, 1993. Hepatology 1994;20(Suppl):63S-68S.
4. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-1847.
5. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort. Hepatology 2001;34:411-416.
6. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998;27:1670-1677.
7. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998;28:585-589.
8. Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001;34:903-910.
9. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP, Boker KHW. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation. Possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001;34:895-902.
10. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against post-transplantation hepatitis B. Liver Transpl 2000;6:429-433.
11. Starkel P, Horsmans Y, Geubel A, Ciccarelli O, Goubau P, Rahier J, Lerut J. Favorable outcome of orthotopic liver transplantation in a patient with subacute liver failure due to emergence of hepatitis B YMDD escape mutant virus. J Hepatol 2001;35:679-681.
12. Saab S, Kim M, Wright TL, Han SH, Martin P, Busuttil RW. Successful orthotopic liver transplantation for lamivudine associated YMDD mutant hepatitis B virus. Gastroenterology 2000; 119:1382-1384.
13. Seehofer D, Rayes N, Naumann U, Neuhaus R, Muller AR, Tullius SG, et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 2001;72:1381-1385.
14. Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003;38:1419-1927.
15. Lo CM, Cheung ST, Ng IO, Liu CL, Lai CL, Fan ST. Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance: Successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin. Liver Transpl 2004;10:557-563.
16. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348: 808-816.
17. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. New Engl J Med 2003;348:800-807.
18. Ono-Nita SK, Kato N, Shiratori Y, Lan KH, Yoshida H, Carrilho FJ, Omata M. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999;103:1635-1640.
19. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998;28:1669-1673.
20. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-134.
21. Yang H, Westland CE, Delaney WE 4th, Heathcote EJ, Ho V, Fry J, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002;36:464-473.
22. Westland CE, Yang H, Delaney WE 4th, Gibbs CS, Miller MD, Wulfsohn M, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003;38:96-103.
23. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292-297.